Welcome to our dedicated page for Genenta Science S.p.A. SEC filings (Ticker: GNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genenta Science S.p.A. filings document a foreign private issuer reporting on Form 6-K, with disclosures incorporated by reference into its Form F-3 registration statement when specified. The record covers material events, shareholder voting matters, capital-structure updates, operating and financial results, and clinical or regulatory disclosures for its biotechnology platform and Temferon program.
The filings also document governance and corporate-structure actions, including the approved expansion of the company’s corporate purpose to sectors covered by Italian Golden Power legislation, board changes, listing-compliance notices, material agreements, and decisions to streamline subsidiaries and finance-function arrangements as Genenta pursues an Italy- and Europe-focused industrial aggregator strategy.
Genenta Science S.p.A. has called an Ordinary and Extraordinary Shareholders’ Meeting for October 29, 2025 in virtual format, with a second-call date on October 30, 2025 if needed. Shareholders will be asked to approve amendments to Article 4 of the company’s by-laws to expand its corporate purpose to include all sectors covered by Italian Golden Power legislation.
They will also vote on increasing the Board of Directors from three to five members and on the appointment of two new board members. The notice of meeting and related materials are to be posted on Genenta’s website under the Investors section on or about September 10, 2025.